This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


BrightPath Biotherapeutics Co., Ltd.
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2017/12/25
Profile

Delegates :
Kenichi Nagai, President and CEO


Incorporated :
May   8 , 2003

Paid in Capital :
3774 Million yen  Increased due IPO and financing after IPO

Employees :
41 人

Address :
2-2-4, Kojimachi, Chiyoda-ku TOKYO
〒102-0083

TEL/FAX :
+81-3-5840-7697 / +81-3-5840-7716

URL:
https://www.brightpathbio.com/english/index.html

Attachment :

Mission/Background :
BrightPath Biotherapeutics, formerly known as GreenPeptide, is a Japan-based clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics. Our pipeline includes cancer peptide vaccine, rejuvenated T cell therapy, and immuno-modulator antibodies. Our basic business model covers research and early clinical development, followed by out-licensing to pharmaceutical companies.

Technology & Business
BrightPath is targeting to research and development of promising drug candidate in the immuno-oncology area. We are conducting clinical studies of novel cancer peptide vaccines, Phase 3 clinical study of ITK-1 in Japan, and Phase 2 study of GRN-1201 in the US. We are also conducting collaborative research to discover novel neoantigen cancer vaccine with Kanagawa Cancer Center.
Regarding cell therapy, we are conducting collaborative research of iPS-T cell therapy with Tokyo University and Juntendo University.
Our next target is fully-personalized cancer vaccine, so we have started collaborative research with National Cancer Center Japan to develop a methodology to identify a target set of neoantigens from the cancer mutations (mutated gene sequence data) in 2017.

Products & Service
Products & Service Name
Stage
Outline
Milestone
ITK-1 (HLA-A24 restricted cancer peptide vaccine)
Phase3
Indication: Castration-resistant prostate cancer. Out-licensed to FUJIFILM corporation in 2011.
Finalising Phase V and key-open
GRN-1201 (HLA-A02 restricted cancer peptide vaccine)
Phase2
Indication: melanoma, non-small cell lung cancer (in combination with immune checkpoint inhibitor)
To acquire effective data regarding concomitant use of an immune checkpoint antibody with a cancer vaccine












Highlights
(ITK-1)
Jun 2015 Performed interim analysis in a phase III clinical trials of ITK-1 in castration-resistant
prostate cancer.
Apr 2016 Finished the enrollment of patients.
(GRN-1201)
Oct 2015 Start of phase I clinical trials of GRN-1201 for malignant melanoma in the U.S.
Jan 2017 Start of phase II clinical trials of GRN-1201 with the concomitant use of an immune checkpoint
antibody against non-small cell lung cancer in the U.S.
Hot news

Alliance strategy
Brightpath is seeking out-licensing partners regarding our promising pipeline and in-licensing/co-development partners to enhance our scientific basis in cancer immunotherapy.

 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.